

## **Study Published in *Journal of Neurotrauma* Offers Promise to Brain Injury Victims**

*Active ingredient of Remedy Pharmaceutical's drug, RP-1127, shown to be effective in treating traumatic brain injury*

New York, NY, USA - December 28, 2009 – Remedy Pharmaceuticals, Inc. today announced that an important preclinical study validating the use of RP-1127 in treating Traumatic Brain Injury (TBI) has been published in the prestigious *Journal of Neurotrauma*.

The study titled “Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion,” clearly shows that in a rat model of severe brain contusion, the active ingredient of RP-1127 is effective in largely eliminated progressive secondary hemorrhage and capillary fragmentation, and was associated with a significant reduction in the size of the necrotic lesion and in preservation of neurobehavioral function.

TBI is the leading cause of death and disability in young people in the United States. TBI happens when a sudden impact causes damage to the brain, which can come from a bump, blow or jolt to the head or even a penetrating head injury. The majority of the 1.4 million TBIs that occur each year are concussions or other forms of mild TBI, and approximately 275,000 TBI victims will experience severe enough trauma that they will be hospitalized. There is no currently approved pharmaceutical therapy for TBI.

Details of the publication follow:

Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. Simard JM, Kilbourne M, Tsybalyuk O, Tosun C, Caridi J, Ivanova S, Keledjian K, Bochicchio G, Gerzanich V. *J Neurotrauma*. 2009 Dec;26(12):2257-67.

### **About RP-1127**

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of  $NC_{Ca-ATP}$  channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

## **About Remedy Pharmaceuticals**

Remedy Pharmaceuticals, Inc. is a development stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: [info@remedypharmaceuticals.com](mailto:info@remedypharmaceuticals.com)